Series C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Umoja ...

SEATTLE, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced new ...

Collaboration to leverage Umoja's VivoVecTM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates "As we ...

SEATTLE, June 15, 2021 /PRNewswire/ -- Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation ...

Umoja Biopharma is a biotechnology company that is focused on developing novel cancer therapies. The company's platform is based on a proprietary technology that enables it to identify and target ...

- First landmark, peer-reviewed publication of successful in vivo CAR T-cell data in an immune competent NHP model -- Data validate the VivoVec™ platform in a translationally relevant model and ...

To address the existing challenges with CAR T-cell therapy, scientists at Umoja Biopharma Inc. developed the Vivovec platform, which is an off-the-shelf surface-engineered lentiviral vector (LVV) drug ...

In less than a year, Umoja Biopharma has made noise with its next-gen CAR-T immunotherapies, a few splashy hires and $263 million in financing. Now the Seattle-based startup is undergoing the next ...

Umoja Biopharma has launched with $53 million in series A financing to develop next-generation CAR T-cell immunotherapies for cancer. Umoja says it has three tricks for improving cell therapies: ...

SEATTLE, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today ...